Roche and Molecular Partners enter into alliance

Partnership will combine novel biologics (DARPins) with Roche drug-conjugate technology

05-Dec-2013 - Roche and Molecular Partners AG announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin® biologics conjugated to toxic agents developed at Roche for the ...

Molecular Partners: Results from Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema

23-Jan-2013 - Molecular Partners announced that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF DARPin, in patients with Diabetic Macular Edema (DME) have been published in The American Journal of Ophthalmology (AJO). MP0112 was shown to be ...

Allergan and Molecular Partners Enter into Exclusive Alliance

Global partnership will develop novel products for eye diseases

23-Aug-2012 - Allergan, Inc. and Molecular Partners AG announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases.Molecular ...

Molecular Partners AG appoints Chief Medical Officer

01-Jun-2012 - Molecular Partners AG announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.Dr. Rojkjaer holds a medical degree from the University of Toronto and is a board-certified hematologist with over 10 years experience in drug development and ...

Molecular Partners comments on Allergan’s progress in Phase IIa Retinal Disease Trial using anti-VEGF DARPin

11-Apr-2012 - Molecular Partners AG commented on the recent progress with its anti-VEGF DARPin (AGN-150998/MP0112), which is being developed in partnership with Allergan for ocular indications. Allergan announced last week at their R&D day that the compound successfully completed phase IIa development. ...

Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc.

13-Dec-2011 - Molecular Partners AG announced that it has entered into a strategic research collaboration and option agreement with Janssen Biotech, Inc. to research, discover and develop DARPin® products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with ...

Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

05-May-2011 - Allergan, Inc. and Molecular Partners AG announced that they have entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin® protein targeting VEGF under investigation for the treatment of retinal diseases.Under the agreement, Allergan obtains exclusive global rights ...

Molecular Partners reports positive results from its first clinical studies

MP0112 is safe and effective in two separate phase I/IIa trials

02-May-2011 - Molecular Partners AG announced that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A. The DARPin molecule was shown to be safe and well tolerated in two separate Phase I/IIa trials in wet age-related macular degeneration (wet AMD) and diabetic ...

Molecular Partners appoints Göran Ando as independent non executive board member

29-Jun-2010 - Molecular Partners AG announced the appointment of Dr Göran Ando as independent non-executive member of the board of directors. Dr Ando brings considerable experience to the board of Molecular Partners, having been CEO of Celltech Group, plc. Prior to this, he was Executive Vice President and ...

Molecular Partners AG collaborates with Centocor Research & Development, Inc.

17-Jan-2008 - Molecular Partners AG announced a collaborative research and license agreement with Centocor Research & Development, Inc. The collaboration will focus on the development of DARPins (Designed Ankyrin Repeat Proteins), a novel class of therapeutic proteins to treat inflammatory diseases. Under the ...